Study of Accuracy of New Diagnostic Technology to Determine Guide Rapid Antibiotic Treatment for Serious Infections

NCT ID: NCT02060513

Last Updated: 2025-12-12

Basic Information

• Recruitment Status: COMPLETED
• Total Enrollment: 2298 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2013-08-31
• Study Completion Date: 2016-11-30

Brief Summary

Military service members and the U.S. veteran population face a growing and serious health threat: widespread antibiotic resistance resulting from resistant bacteria and a dwindling pipe-line of sufficiently potent antibiotics. Infections with antibiotic resistant bacteria are increasing significantly. They cause major complications and mortality, and drive up healthcare costs. Powerful but non-targeted antibiotics, while in widespread use, can actually pressure bacteria to develop resistance.

Detailed Description

Current methods for diagnosing infections typically require 2-3 days to produce results that can guide antibiotic choice. That is frequently too delayed to help clinicians make good treatment decisions. This also results in inappropriate or over-treatment with non-targeted antibiotics that are started while awaiting lab results. More rapid technologies that can accurately diagnose the specific cause of an infection could guide early, targeted antibiotic treatment. This would result in more effective early treatment of infection, decrease unnecessary exposure to excess antibiotics, and could slow the development of antibiotic resistance. By diagnosing infections earlier, we expect to reduce the complications and mortality of combat-related infections in Wounded Warriors and Military Veterans.

We propose a new ultra-rapid technology (called MADM) that uses a digital microscope to detect bacteria growing directly from a patient's specimen, rather than waiting for growth in lab cultures. The innovative new method supports identification of the infecting bacteria within 2 hours of receiving a specimen. The technology also shows the effect of selected antibiotics on the bacteria including multidrug resistant bacteria so that doctors know within 6 hours from specimen collection which antibiotic kills the bacteria.

This study involves collection of any excess volume of microbiology specimens after it has been determined sufficient sample is available for clinical care. All microbiological samples and results are being obtained for solely non-research purposes as part of usual care; only leftover/discarded materials from clinical or research procedures already performed will be used for this study. Samples will be tested in tandem with usual care on the new technology to test the accuracy and speed. Results obtained from the new technology will not be used in patient care or to make treatment decisions.

Conditions

Infection; Skin and Subcutaneous Tissue Bacterial Infections; Healthcare-associated Infection; Infection Due to Resistant Bacteria

Study Design

• Observational Model Type: CASE_CONTROL
• Study Time Perspective: PROSPECTIVE

Eligibility Criteria

Inclusion Criteria

• Age ≥ 18 years old.
• Microbiology culture (respiratory, blood or tissue/skin) ordered during regular clinical care.

Exclusion Criteria

• Insufficient sample volume available after clinical test completed.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

United States Department of Defense

FED

Sponsor Role: collaborator

Accelerate Diagnostics, Inc.

INDUSTRY

Sponsor Role: collaborator

Connie Price

OTHER

Sponsor Role: lead

Responsible Party

Connie Price

Professor

Responsibility Role: SPONSOR_INVESTIGATOR

Principal Investigators

Connie S Price, MD

Role: PRINCIPAL_INVESTIGATOR

Denver Health Medical Center

Ivor S Douglas, MD

Role: PRINCIPAL_INVESTIGATOR

Denver Health Medical Center

Locations

Denver Health Medical Center

Denver, Colorado, United States

Denver Veterans Affairs Eastern Colorado Health Care System

Denver, Colorado, United States

Washington Hospital Center

Washington D.C., District of Columbia, United States

Countries

United States

Other Identifiers

W81XWH-12-2-0085

Identifier Type: OTHER

Identifier Source: secondary_id

12-1580

Identifier Type: -

Identifier Source: org_study_id